NYSE:ENOV - Enovis Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $67.33
  • Forecasted Upside: 24.95 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$53.89
▼ -2.11 (-3.77%)

This chart shows the closing price for ENOV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Enovis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ENOV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ENOV

Analyst Price Target is $67.33
▲ +24.95% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Enovis in the last 3 months. The average price target is $67.33, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 24.95% upside from the last price of $53.89.

This chart shows the closing price for ENOV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 3 contributing investment analysts is to hold stock in Enovis.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/11/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/28/2022ArgusInitiated CoverageHoldLow
6/27/2022Loop CapitalReiterated RatingBuy$68.00Low
6/16/2022Wells Fargo & CompanyInitiated CoverageEqual Weight$61.00High
5/11/2022Robert W. BairdLower Price Target$79.00 ➝ $73.00Low
(Data available from 7/5/2017 forward)

News Sentiment Rating

0.34 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/7/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/6/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/5/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/7/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/6/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/6/2022
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/5/2022
  • 3 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/5/2022

Current Sentiment

  • 3 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Enovis logo
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.
Read More

Today's Range

Now: $53.89
Low: $53.60
High: $56.28

50 Day Range

MA: $62.68
Low: $55.00
High: $67.56

52 Week Range

Now: $53.89
Low: $54.33
High: $164.01

Volume

4,012 shs

Average Volume

421,847 shs

Market Capitalization

$2.91 billion

P/E Ratio

42.42

Dividend Yield

N/A

Beta

2.18

Frequently Asked Questions

What sell-side analysts currently cover shares of Enovis?

The following Wall Street research analysts have issued reports on Enovis in the last year: Argus, Loop Capital, Robert W. Baird, and Wells Fargo & Company.
View the latest analyst ratings for ENOV.

What is the current price target for Enovis?

0 Wall Street analysts have set twelve-month price targets for Enovis in the last year. Their average twelve-month price target is $67.33, suggesting a possible upside of 24.9%.
View the latest price targets for ENOV.

What is the current consensus analyst rating for Enovis?

Enovis currently has 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ENOV, but not buy more shares or sell existing shares.
View the latest ratings for ENOV.

How do I contact Enovis' investor relations team?

Enovis' physical mailing address is 2711 Centerville Road Suite 400, Wilmington DE, 19808. The company's listed phone number is 302 252 9190 and its investor relations email address is [email protected] The official website for Enovis is www.enovis.com. Learn More about contacing Enovis investor relations.